The Human Radiation Use Committee (HRUC) and The Radioactive Drug Research Committee (RDRC) are subcommittees under the UW-Madison & UW Health Executive Radiation Safety Committee.  Radiation and radioactive material uses in research requiring HRUC or RDRC review include the following:

  • Radiologic procedures that are administered solely for experimental or research purposes (i.e., would not otherwise be administered)
  • Use of an investigational radiologic device or investigational radiopharmaceutical (e.g., contrast agent, radionuclide)
  • Use of radiologic procedures when these procedures are the subject of the investigation (e.g., comparison of radiotherapy delivery methods)
  • Standard of care procedures that are being altered as part of research

Radiologic procedures that are administered in addition to those that the participant would receive as part of standard medical care (i.e., “extra” procedures).

For questions regarding the process or on how to submit information, contact:

This is an accordion element with a series of buttons that open and close related content panels.


HRUC reviews and approves applications involving the clinical administration of radiopharmaceuticals or radioactive drugs for routine medical patients or the administration of radioactive drugs to human research subjects involving FDA-approved:

  • New Drug Applications (NDA)
  • Investigational New Drugs (IND)
  • IND Exemptions.

A HRUC application can involve the clinical administration of radiopharmaceuticals intended for therapeutic use, diagnostic use, or similar purposes or to determine the safety and effectiveness of a drug (clinical trials).

An example of a HRUC study would be an investigator wanting to study a new radioligand to monitor the treatment response of a brain tumor.

Number of Subjects

There is no limit on the number of research subjects allowed for a given HRUC study.  However, the HRUC will evaluate the number of requested research subjects and determine if the number appears appropriate for the study.

Exposure Limits for Human Subjects

There are no regulatory dose limits for HRUC applications; however, the HRUC will evaluate each research study for safety on a case-by-case basis.


The RDRC reviews research protocols, as required by the Food and Drug Administration (FDA) regulation 21 CFR 361.1, involving radiopharmaceuticals without:

  • A New Drug Application (NDA) filed with the FDA
  • An approved Investigational New Drug (IND) application
  • An IND Exemption that may be subject to review by the RDRC in compliance with 21 CFR 361.1.

To be eligible for review by the RDRC under 21 CFR 361.1, a protocol must:

  • Involve certain radioactive compounds generally recognized as safe and effective
  • Be designed to use radioactive compounds to obtain basic information regarding the metabolism of the compound or regarding human physiology, pathophysiology, or biochemistry
  • Not be intended for immediate therapeutic use, diagnostic use, diagnostic studies, or clinical trials
  • Not be intended to determine the safety and effectiveness of a drug (carry out a clinical trial)
  • Not be designed as part of the routine clinical medical management of patients
  • Not allow a pharmacological dose to cause a clinically detectable effect
  • Be limited with respect to the annual and total radiation dose commitment to the numerical limits specified in 21 CFR 361.1

An example of a RDRC study would be an investigator wanting to study the expression of a specific neurotransmitter receptor in the brain.

Number of Subjects

The Principal Investigator (PI) must never study more than the maximum number of research subjects approved by the RDRC.  For example, if the RDRC approved a research protocol for n=20 subjects, the PI or study group must not exceed n=20 without first seeking and obtaining approval from the RDRC.

In addition, RDRC studies must never exceed the FDA limit of 30 research subjects (21 CFR 361.1) without prior approval by the RDRC.  If an approved RDRC proposal intends to exceed more than 30 research subjects, the PI must:

  • Notify the RDRC in advance of exceeding the approved 30 research subjects
  • Complete and submit to the RDRC an FDA Form-2915 and justification cover-letter

Then, the RDRC must approve the request and submit the study to the FDA.

Multi-arm study protocols may have a different number of approved research subjects authorized by the IRB for the ‘total’ protocol; however, there may be a more limited approval for research subjects undergoing a research procedure with administration of a radiopharmaceutical.  Thus, the IRB ‘maximum’ number of approved research subjects may not be the same maximum number approved by the RDRC.

Exposure Limits for Human Subjects

Per the FDA regulatory limits, the maximum allowed human dosimetry per year per human research subject is the smallest dose with which it is practical to perform the study without jeopardizing the benefits to be obtained from the study.  When determining the total radiation doses (effective dose) and dose commitments, the following procedures must be considered:

  • All radioactive material included in the radiopharmaceutical either as essential material or as significant contaminant or impurity
  • X-ray procedures that are part of the research study
  • Possibility of follow-up studies

Under no circumstances may the radiation dose to an adult research subject from a single study or cumulatively from a number of studies conducted within 1-year be generally recognized as safe if such dose exceeds the following criteria:

  • Whole Body / Active Blood-Forming Organs / Lens of Eye / Gonads (FDA Limits)
    • Single Dose (Effective Dose) = 3 rem (0.03 Sv)
    • Annual & Total Effective Dose Commitment = 5 rem (0.05 Sv)
  • Other Organs: Single Dose = 5 rem (0.05 Sv)
  • Annual and Total Dose Commitment = 15 rem (0.15 Sv)

Reports for RDRC Approved Research Studies

  • RDRC Adverse Events: ALL adverse effects or adverse reactions (mild or severe) that are probably attributable to the use of the radio-pharmaceutical or radioactive tracer in a research study MUST be reported to the RDRC no later than three calendar days after the identification of the adverse effect or reaction by contacting Guy Bolling.
  • You need not confirm a causal relationship between the drug and the event, but the likelihood that the event and the use of the drug were related.
  • RDRC Quarterly Reports: These reports track when a subject receives the first administration of a radio-pharmaceutical and are used to track the number of approved “Unique Subjects” as they are studied each quarter.  The RDRC generates and sends blank RDRC quarterly reports to each study group.  The study groups are required to complete and return the quarterly report to RDRC by email or fax.  An Excel spreadsheet can be used to track when each subject is studied and what the organ doses were for each administration of radio-pharmaceutical.
  • RDRC Annual Report (FDA Form 2915): The FDA requires that the RDRC submits an “Annual Report” by January 31 of each year.  The report must contain a summary of study information for each study conducted during the preceding year, including the number of “Unique Subjects” that were studied.  The PI must submit a completed FDA Form 2915 (‘Annual Report’) for each of their RDRC-approved research projects to the RDRC.  The RDRC reviews, revises if necessary, and sends the report to the FDA.  Please note that the sum of the Quarterly Reports and the Annual Report totals of “Unique Subjects” studied for each calendar year must match.  Current versions of the FDA Form 2915 (‘Report on Research Use of Radioactive Drugs – Study Summary’) are posted on the FDA website.  The FDA will not accept an outdated version of FDA Form 2015.  Check the FDA website each time before completing the form.
  • RDRC Special Summary Report (FDA Form-2915): This summary notifies the FDA that a protocol involving more than 30 research subjects has been approved or that a previously-approved protocol is expanded to include more than 30 subjects.  The PI must complete the “Special Summaries” of FDA Form 2915 (‘Report on Research Use of Radioactive Drugs – Study Summary’) form and a justification letter and submit them to the RDRC for approval.  Upon approval, the RDRC will submit it to the FDA

X-Ray/Appendix M

Chapter DHS 157 | APPENDIX M

Information to be Submitted by Persons
Proposing to Conduct Healing Arts Screening

Persons requesting that the department approve a healing arts screening program shall submit the following information and evaluation. Mammography screening, bone density screening and National Cancer Institute approved low dose CT lung screening are exempt from this requirement unless persons under age 18 are involved:

a. Name and address of the applicant and, where applicable, the names and addresses of agents within this state.

b. Diseases or conditions for which the x−ray examinations are to be used in diagnoses.

c. A detailed description of the x−ray examinations proposed in the screening program.

d. A description of the population to be examined in the screening program, which is age, sex, physical condition, and other appropriate information. If the study involves women of reproductive age and the exam involves the trunk of the body, what precautions are being taken to ensure the subjects are not pregnant.

e. An evaluation of any known alternate methods not involving ionizing radiation which could achieve the goals of the screening program and why these methods are not used instead of the x−ray examinations.

f. An evaluation by a medical physicist of the x−ray system to be used in the screening program. The evaluation by the medical physicist shall show that the system satisfies all requirements of this chapter. The evaluation shall include a measurement of patient exposures from the x−ray examinations to be performed. This exposure information must be included in the informed consent papers signed by the subject. An explanation
of the risk from the radiation exposure shall be included in the informed consent if the head, neck or trunk is involved in the procedure.

g. The name and address of the individual who will interpret the radiograph or images if any are produced. The interpreting physicians must be licensed in Wisconsin.

h. A description of the procedures to be used in advising the individuals screened and their private practitioners of the healing arts of the results of the screening procedure and any further medical needs indicated.

i. A description of the procedures for the retention or disposition of the radiographs, images, graphs and other records pertaining to the x−ray examinations.

j. An indication of the frequency of screening and the duration of the entire screening program.

k. Human−use committee approval of the screening program if one is required by local policy.

l. A copy of the informed consent information being provided to the subjects.
m. If minors are involved, parental consent is required.

Radiation Risk Language

The radiation dose to your body from these kinds of imaging scans is termed the ‘effective dose’ and is measured in terms of Sieverts (Sv) or milliSieverts (mSv; 1/1000 Sv).  The total amount of radiation an average size adult will be exposed to in this study will be _____mSv.  This radiation exposure will be added to your overall lifetime radiation risk.  Your lifetime radiation risk includes the natural background radiation you are exposed to naturally like everyone else living on this planet, which is on average 3 mSv per year; the maximum radiation you will be exposed to in this study is _____ times [higher or lower] than the average yearly background radiation.  In terms of radiation a person may get exposed to during medical care, the maximum amount of radiation you could receive for research purposes in this study if you complete the study is about ______ [%, fraction, or times] the radiation received in CT scan (~10 mSv) of the abdomen and pelvis.

The U.S. federal government requires that the annual amount of radiation exposure of radiation workers does not exceed 50 mSv per year; the radiation you will be exposed to in this study is ______ [%, fraction, or times] this amount.

Please tell us if you have had any major radiation exposure in the past, particularly in the last two years; such as treatment with x-rays, radioactivity, diagnostic x-rays, CT scans, or nuclear medicine scans.  It is also important that you inform the investigators of your participation in any other research studies during the past year.

IRB Approval for HRUC or RDRC Approved Protocols

Any protocol submitted to the HRUC or RDRC for review and approval is also required to receive IRB approval.  IRB approval is contingent upon HRUC or RDRC review and approval and any revisions or modifications required by the HRUC or RDRC must be incorporated into the protocol before final, full approval by the IRB will be granted.

Amending an HRUC or RDRC Previously-Approved Protocol

The HRUC or RDRC must review any amendment to a previously-approved eResearch protocol if any of the following changes have been made:

  • Change in PI
  • Change in radiopharmaceutical/radionuclide tracer use in the protocol (additions or deletions)
  • Change in radiopharmaceutical activity (increase or decrease) administered to a research subject
  • Change in the anticipated radiation exposure to a research subject
  • Increase in the number of research subjects to be studied
    • RDRC approved studies must submit an FDA Form 2915 (“Special Summary”) and a justification letter to the RDRC when requesting approval to study more than 30 research subjects
    • Check the FDA website for the most current version of FDA Form 2915 (expired versions will not be accepted by the FDA)
  • An adverse event (AE) occurs that involves a radiopharmaceutical or radioactive drug
  • Other Reportable Information or Occurrence (ORIO) takes place involving a radiopharmaceutical
  • Study has ended enrollment and is now open only for data analysis

Supplemental Information